The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Malfait, A. M.; Gallily, R.; Sumariwalla, P. F.; Malik, A. S.; Andreakos, E.; Mechoulam, R.; Feldmann, M.

doi:10.1073/pnas.160105897

Cited by 669Cannabis and Cannabinoid ResearchNatural Compounds in Disease TreatmentRheumatoid Arthritis Research and Therapies

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Open access

Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., Feldmann, M.·2000·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.160105897PMC PMC16904

Open this paper in CoChat — free account

Abstract

The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA). CIA was elicited by immunizing DBA/1 mice with type II collagen (CII) in complete Freund's adjuvant. The CII used was either bovine or murine, resulting in classical acute CIA or in chronic relapsing CIA, respectively. CBD was administered after onset of clinical symptoms, and in both models of arthritis the treatment effectively blocked progression of arthritis. CBD was equally effective when administered i.p. or orally. The dose dependency showed a bell-shaped curve, with an optimal effect at 5 mg/kg per day i.p. or 25 mg/kg per day orally. Clinical improvement was associated with protection of the joints against severe damage. Ex vivo, draining lymph node cells from CBD-treated mice showed a diminished CII-specific proliferation and IFN-γ production, as well as a decreased release of tumor necrosis factor by knee synovial cells. In vitro effects of CBD included a dose-dependent suppression of lymphocyte proliferation, both mitogen-stimulated and antigen-specific, and the blockade of the Zymosan-triggered reactive oxygen burst by peritoneal granulocytes. It also was found that CBD administration was capable of blocking the lipopolysaccharide-induced rise in serum tumor necrosis factor in C57/BL mice. Taken together, these data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.160105897

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Administration of CBD or its synthetic analogs attenuates clinical signs of arthritis and joint damage in CIA.
“Administration of CBD, or its synthetic analogs, attenuates clinical signs of arthritis and joint damage, while having an immunosuppressant effect in CIA (Haj et al, 2015;Malfait et al, 2000;Sumariwalla et al, 2004).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Malfait et al, 2000
Administration of CBD or its synthetic analogs has an immunosuppressant effect in CIA.
“Administration of CBD, or its synthetic analogs, attenuates clinical signs of arthritis and joint damage, while having an immunosuppressant effect in CIA (Haj et al, 2015;Malfait et al, 2000;Sumariwalla et al, 2004).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Malfait et al, 2000

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · see citing works
delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages.
McCoy, K. L., Gainey, D., & Cabral, G. A. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09609-0 · Cited by 74 · see citing works

Flagged first, then by citations

Research works printed but not linked: 44

[1]Mechoulam R, Shvo Y. Tetrahedron. 1963;19:2073–2078. doi: 10.1016/0040-4020(63)85022-x. [DOI] [PubMed] [Google Scholar] · DOI
[2]Mechoulam R. Science. 1970;168:1159–1166. doi: 10.1126/science.168.3936.1159. [DOI] [PubMed] [Google Scholar] · DOI
[3]Turner C F, Elsohly M A, Boeren E C. J Nat Prod. 1980;43:169–234. doi: 10.1021/np50008a001. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
[4]Razdan R K. Pharmacol Rev. 1986;38:75–149. [PubMed] [Google Scholar]
[5]Mechoulam R, Devane W A, Glaser R. In: Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Murphy L, Bartke A, editors. Boca Raton, FL: CRC; 1992. pp. 1–33. [Google Scholar]
[6]Klein T W, Newton C, Friedman H. Immunol Today. 1998;19:373–380. doi: 10.1016/s0167-5699(98)01300-0. [DOI] [PubMed] [Google Scholar] · DOI
[7]Specter S, Lancz G, Hazelden J. Int J Immunopharmacol. 1990;12:261–267. doi: 10.1016/0192-0561(90)90081-w. [DOI] [PubMed] [Google Scholar] · DOI
[8]Klein T W, Kawakami Y, Newton C, Friedman H. J Toxicol Environ Health. 1991;32:465–477. doi: 10.1080/15287399109531496. [DOI] [PubMed] [Google Scholar] · DOI
[9]Cabral G A, Pettit D A, Fisher-Stenger K. In: Drugs of Abuse, Immunity, and Immunodeficiency. Friedman H, editor. New York: Plenum; 1993. pp. 93–105. [Google Scholar]
[10]McCoy K L, Gainey D, Cabral G A. J Pharmacol Exp Ther. 1995;273:1216–1223. [PubMed] [Google Scholar]
[11]Coffey R G, Yamamoto Y, Snella E, Pross S. Biochem Pharmacol. 1996;52:743–751. doi: 10.1016/0006-2952(96)00356-5. [DOI] [PubMed] [Google Scholar] · DOI
[12]Formukong E A, Evans A T, Evans F J. Inflammation. 1988;12:361–371. doi: 10.1007/BF00915771. [DOI] [PubMed] [Google Scholar] · DOI
[13]Watzl B, Scuderi P, Watson R R. Int J Immunopharmacol. 1991;13:1091–1097. doi: 10.1016/0192-0561(91)90160-9. [DOI] [PubMed] [Google Scholar] · DOI
[14]Srivastava M D, Srivastava B I S, Brouhard B. Immunopharmacology. 1998;40:179–185. doi: 10.1016/s0162-3109(98)00041-1. [DOI] [PubMed] [Google Scholar] · DOI
[15]Rosenkrantz H, Fleischman R W, Grant R J. Toxicol Appl Pharmacol. 1981;58:118–131. doi: 10.1016/0041-008x(81)90122-8. [DOI] [PubMed] [Google Scholar] · DOI
[16]Courtenay J S, Dallman M J, Dayan A D, Martin A, Mosedale B. Nature (London) 1980;283:666–668. doi: 10.1038/283666a0. [DOI] [PubMed] [Google Scholar] · DOI
[17]Ranges G E, Sriram S, Cooper S M. J Exp Med. 1985;162:1105–1110. doi: 10.1084/jem.162.3.1105. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
[18]Seki N, Sudo Y, Yoshioka T, Sugihar S, Fujitsu T, Sakuma S, Ogawa T, Hamaoka T, Senoh H, Fujiwara H. J Immunol. 1988;140:1477–1484. [PubMed] [Google Scholar]
[19]Mauri C, Williams R O, Walmsley M, Feldmann M. Eur J Immunol. 1996;26:1511–1514. doi: 10.1002/eji.1830260716. [DOI] [PubMed] [Google Scholar] · DOI
[20]Thorbecke G J, Shah R, Leu C H, Kuruvilla A P, Hardison A M, Palladino M A. Proc Natl Acad Sci USA. 1992;89:7375–7379. doi: 10.1073/pnas.89.16.7375. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
[21]Williams R O, Feldmann M, Maini R N. Proc Natl Acad Sci USA. 1992;89:9784–9788. doi: 10.1073/pnas.89.20.9784. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
[22]Feldmann M, Elliot M J, Woody J N, Maini R N. Adv Immunol. 1997;64:243–350. doi: 10.1016/s0065-2776(08)60891-3. [DOI] [PubMed] [Google Scholar] · DOI
[23]Gaoni Y, Mechoulam R. J Am Chem Soc. 1971;93:217–224. doi: 10.1021/ja00730a036. [DOI] [PubMed] [Google Scholar] · DOI
[24]Sher T, Rottern S, Gallily R. Cancer Immunol Immunother. 1990;31:86–92. doi: 10.1007/BF01742371. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
[25]Gerlier D, Thomasset N. J Immunol Methods. 1986;94:57–61. doi: 10.1016/0022-1759(86)90215-2. [DOI] [PubMed] [Google Scholar] · DOI
[26]Malfait A M, Butler D M, Presky D H, Maini R N, Brennan F M, Feldmann M. Clin Exp Immunol. 1998;111:377–383. doi: 10.1046/j.1365-2249.1998.00485.x. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
[27]Butler D M, Malfait A M, Mason L J, Warden P J, Kollias G, Maini R N, Feldmann M, Brennan F M. J Immunol. 1997;159:2867–2876. [PubMed] [Google Scholar]
[28]Espevik T, Nissen-Meyer J. J Immunol Methods. 1986;95:99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar] · DOI
[29]Baker D, Butler D, Scallon B J, O'Neill J K, Turk J L, Feldmann M. Eur J Immunol. 1994;24:2040–2048. doi: 10.1002/eji.1830240916. [DOI] [PubMed] [Google Scholar] · DOI
[30]Holmdahl R, Jansson R, Larsson E, Rubin K, Klareskog L. Arthritis Rheum. 1986;29:106–113. doi: 10.1002/art.1780290114. [DOI] [PubMed] [Google Scholar] · DOI
[31]Boissier M C, Feng X Z, Carlioz A, Roudier R, Fournier C. Ann Rheum Dis. 1987;46:691–700. doi: 10.1136/ard.46.9.691. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
[32]Sulcova E, Mechoulam R, Fride E. Pharmacol Biochem Behav. 1998;59:347–353. doi: 10.1016/s0091-3057(97)00422-x. [DOI] [PubMed] [Google Scholar] · DOI
[33]Butler D M, Malfait A M, Maini R N, Brennan F M, Feldmann M. Eur J Immunol. 1999;29:2205–2212. doi: 10.1002/(SICI)1521-4141(199907)29:07<2205::AID-IMMU2205>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar] · DOI
[34]Hampson A J, Grimaldi M, Axelrod J, Wink D. Proc Natl Acad Sci USA. 1998;95:8268–8273. doi: 10.1073/pnas.95.14.8268. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
[35]Mechoulam R, Hanus L, Fride E. Progr Med Chem. 1998;35:199–243. doi: 10.1016/s0079-6468(08)70037-7. [DOI] [PubMed] [Google Scholar] · DOI
[36]Zurier R B, Rossetti R G, Lane J H, Goldberg J M, Hunter S A, Burstein S H. Arthritis Rheum. 1998;41:163–170. doi: 10.1002/1529-0131(199801)41:1<163::AID-ART20>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar] · DOI
[37]Adams I B, Martin B R. Addiction. 1996;91:1585–1614. [PubMed] [Google Scholar]
[38]Patrini G, Sacerdote P, Fuzio D, Manfred B, Parolaro D. J Neuroimmunol. 1997;80:143–148. doi: 10.1016/s0165-5728(97)00149-5. [DOI] [PubMed] [Google Scholar] · DOI
[39]Cunha J M, Carlini E A, Pereira A E, Ramos O L, Pimentel C, Gagliardi R, Sanvito W L, Lander N, Mechoulam R. Pharmacology. 1980;21:175–185. doi: 10.1159/000137430. [DOI] [PubMed] [Google Scholar] · DOI
[40]Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K. Pharmacol Biochem Behav. 1991;40:701–708. doi: 10.1016/0091-3057(91)90386-g. [DOI] [PubMed] [Google Scholar] · DOI
[41]Zuardi A W, Guimaraes F S, Moreira A C. Brazil J Med Biol Res. 1993;26:213–217. [PubMed] [Google Scholar]
[42]Devane W A, Dysarz F A, Johnson M R, Melvin L S, Howlett A C. Mol Pharmacol. 1988;34:605–613. [PubMed] [Google Scholar]
[43]Munro S, Thomas K L, Abu-Shaar M. Nature (London) 1993;365:61–65. doi: 10.1038/365061a0. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
[44]Thomas B F, Gilliam A F, Burch D F, Roche M J, Seltzman H H. J Pharmacol Exp Ther. 1998;285:285–292. [PubMed] [Google Scholar]

Sorted by citations

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · see citing works
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102 · see citing works
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728 · see citing works
The pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724 · see citing works
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622 · see citing works
Cannabinoids as Novel Anti-Inflammatory Drugs
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.93 · Cited by 555 · see citing works
“CBD is the major nonpsychoactive component of the cannabis plant and its protective effect has been shown in murine collagen-induced arthritis [85].”
Cannabidiol—recent advances
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · see citing works
Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression
Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497 · see citing works
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006) · Rheumatology · doi:10.1093/rheumatology/kei183 · Cited by 433 · see citing works
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · see citing works
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407 · see citing works
Self-citation
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
Costa, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.006 · Cited by 395 · see citing works
Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats
Campos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364 · see citing works
Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?
McPartland, J. M., & Russo, E. B. (2001) · Journal of Cannabis Therapeutics · doi:10.1300/j175v01n03_08 · Cited by 321 · see citing works
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307 · see citing works
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies
Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03674.x · Cited by 305 · see citing works
The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301 · see citing works
Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255 · see citing works
Self-citation
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis
McAllister, S. D., Murase, R., Christian, R. T., Lau, D., Zielinski, A. J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1177-4 · Cited by 229 · see citing works
Beyond THC and Endocannabinoids
Pacher, P., Kogan, N. M., & Mechoulam, R. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021441 · Cited by 175 · see citing works
Self-citation
Cannabinoid-Induced Immune Suppression and Modulation of Antigen-Presenting Cells
Klein, T. W., & Cabral, G. A. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-005-9007-x · Cited by 172 · see citing works
Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acidin vivoby mechanisms independent of the activation of cannabinoid, vanilloid TRPV1and adenosine A2Areceptors
Sagredo, O., Ramos, J. A., Decio, A., Mechoulam, R., & Fernández‐Ruiz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05717.x · Cited by 147 · see citing works
Self-citation
Δ9-Tetrahydrocannabinol-Induced Apoptosis in the Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in Vivo
McKallip, R. J., Lombard, C., Martin, B. R., Nagarkatti, M., & Nagarkatti, P. S. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033506 · Cited by 143 · see citing works
Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors
Campos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.012 · Cited by 139 · see citing works
A novel synthetic, nonpsychoactive cannabinoid acid (HU‐320) with antiinflammatory properties in murine collagen‐induced arthritis
Sumariwalla, P. F., Gallily, R., Tchilibon, S., Fride, E., Mechoulam, R., & Feldmann, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20050 · Cited by 134 · see citing works
Self-citation
Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease
Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129 · see citing works
Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture
Cassol-Jr, O. J., Comim, C. M., Silva, B. R., Hermani, F. V., Constantino, L. S., Felisberto, F., Petronilho, F., Hallak, J. E. C., De Martinis, B. S., Zuardi, A. W., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.023 · Cited by 94 · see citing works
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects
Hallak, J. E. C., Dursun, S. M., Bosi, D. C., de Macedo, L. R. H., Machado-de-Sousa, J. P., Abrão, J., Crippa, J. A. S., McGuire, P., Krystal, J. H., Baker, G. B., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.002 · Cited by 83 · see citing works
A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis
Malek, N., Mrugala, M., Makuch, W., Kolosowska, N., Przewlocka, B., Binkowski, M., Czaja, M., Morera, E., Di Marzo, V., & Starowicz, K. (2015) · Pain · doi:10.1097/j.pain.0000000000000132 · Cited by 63 · see citing works
Expression of Cannabinoid Receptors in Human Osteoarthritic Cartilage: Implications for Future Therapies
Dunn, S. L., Wilkinson, J. M., Crawford, A., Bunning, R. A. D., & Le Maitre, C. L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0001 · Cited by 62 · see citing works
Arthritis and cannabinoids: HU-210 and Win-55,212–2 prevent IL-1 α-induced matrix degradation in bovine articular chondrocytes in-vitro
Mbvundula, E. C., Bunning, R. A. D., & Rainsford, K. D. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.3.0009 · Cited by 59 · see citing works
Traditional uses of Cannabis: An analysis of the CANNUSE database
Balant, M., Gras, A., Ruz, M., Vallès, J., Vitales, D., & Garnatje, T. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114362 · Cited by 58 · see citing works
The type 2 cannabinoid receptor regulates susceptibility to osteoarthritis in mice
Sophocleous, A., Börjesson, A. E., Salter, D. M., & Ralston, S. H. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.04.020 · Cited by 54 · see citing works
Cannabinoid WIN-55,212-2 mesylate inhibits interleukin-1β induced matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression in human chondrocytes
Dunn, S. L., Wilkinson, J. M., Crawford, A., Le Maitre, C. L., & Bunning, R. A. D. (2014) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2013.10.016 · Cited by 46 · see citing works
Cannabis for Chronic Pain: Case Series and Implications for Clinicians
Ware, M. A., Gamsa, A., Persson, J., & Fitzcharles, M.-A. (2002) · Pain Research and Management · doi:10.1155/2002/380509 · Cited by 38 · see citing works
Brief Commentary: Cannabinoid Dosing for Chronic Pain Management
Boehnke, K. F., & Clauw, D. J. (2019) · Annals of Internal Medicine · doi:10.7326/m18-2972 · Cited by 23 · see citing works

Authors: Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M.
Affiliations: Hebrew University of Jerusalem (IL)
ORCID: Malfait, A. M.
Gallily, R.
Andreakos, E.
Mechoulam, R.
Feldmann, M.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2000-08
Volume: 97
Issue: 17
Pages: 9561-9566
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.160105897
PMC: PMC16904
OpenAlex: W1996081689
Cited by: 669
References: 2
Citations by year: 2026: 19 · 2025: 24 · 2024: 36 · 2023: 41 · 2022: 46 · 2021: 57 · 2020: 36 · 2019: 34 · 2018: 25 · 2017: 18 · 2016: 21 · 2015: 23 · 2014: 11 · 2013: 20 · 2012: 25
FWCI: 9.71
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords: cannabidiol, collagen-induced arthritis, arthritis treatment, oral administration, immunosuppression, anti-inflammatory activity, type II collagen, lymphocyte proliferation, interferon-gamma, TNF-α, granulocytes, synoviocytes
MeSH terms: Administration, Oral, Animals, Arthritis, Cannabidiol, Cannabis, Cattle, Cell Division, Collagen, Disease Models, Animal, Dose-Response Relationship, Drug, Granulocytes, Hindlimb, Interferon-gamma, Joints, Lipopolysaccharides, Lymph Nodes, Lymphocyte Activation, Male, Mice, Inbred C57BL, Mice, Inbred DBA, Peritoneum, Synovial Fluid, Tumor Necrosis Factor-alpha, Zymosan, Reactive Oxygen Species, Th1 Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Record

About these checks